AstraZeneca Executive and Leadership Team

Iris Zhang, the Chief Financial Officer at AstraZeneca, directs the overarching fiscal strategy and capital allocation for the global biopharmaceutical enterprise. Zhang manages the integrity of financial reporting while ensuring that investment in research and development aligns with long-term growth objectives. By overseeing the balance sheet and liquidity management, the Chief Financial Officer maintains the financial health necessary to support the discovery of innovative prescription medicines. This leadership role involves constant collaboration with the Board to optimize resource distribution across oncology, cardiovascular, and immunology portfolios. Iris Zhang monitors global market trends to mitigate economic risks, ensuring that the company remains competitive in the complex pharmaceutical landscape. Through rigorous financial planning and analysis, the Chief Financial Officer secures the capital required to advance the pipeline of life-saving treatments, ultimately driving sustainable value for shareholders and patients worldwide.

Aaron Kroft, the Chief Financial Officer, Enterprise Cell Therapy Unit at AstraZeneca, manages the financial architecture specifically for the advanced cell therapy division. Kroft oversees the budgeting and cost-efficiency programs required to scale complex manufacturing processes for next-generation therapies. By analyzing the return on investment for clinical trials, the Chief Financial Officer, Enterprise Cell Therapy Unit ensures that the unit maintains a focus on high-impact patient outcomes. This role requires close coordination with research teams to align funding with the rapid development cycles inherent in cell therapy innovation. Aaron Kroft evaluates the financial feasibility of new technology acquisitions, supporting the broader mission of the company to lead in specialized medicine. Through precise financial modeling and operational oversight, the Chief Financial Officer, Enterprise Cell Therapy Unit facilitates the transition of experimental treatments into viable commercial products, strengthening the market position of the organization in the competitive immunology space.

Joey Zhu, the Chief Financial Officer, PA To The at AstraZeneca, coordinates the financial administrative functions and executive support systems that underpin the corporate leadership team. Zhu manages the flow of critical financial data to the executive office, ensuring that decision-makers possess accurate information regarding regional performance and operational expenditures. By streamlining the reporting processes, the Chief Financial Officer, PA To The enhances the efficiency of the executive suite in managing the global biopharmaceutical portfolio. This role involves facilitating communication between financial departments and senior leadership to ensure alignment on strategic goals. Joey Zhu monitors the administrative budget and resource allocation, maintaining the operational standards required for a global leader in prescription medicine. Through the management of executive financial workflows, the Chief Financial Officer, PA To The supports the overall agility of the organization, allowing the company to respond rapidly to shifts in the global healthcare market.

Santiago Rivera, the Chief Financial Officer & Chief Financial Officer, Andean Cluster at AstraZeneca, oversees the financial operations for the Andean region while contributing to the broader corporate fiscal strategy. Rivera manages regional revenue growth, tax compliance, and local market investment strategies to ensure the commercial success of the pharmaceutical portfolio. By directing the financial planning for the Andean Cluster, the Chief Financial Officer & Chief Financial Officer, Andean Cluster optimizes the distribution of resources to meet the specific healthcare needs of the region. This role involves navigating complex regulatory environments and currency fluctuations to maintain profitability. Santiago Rivera collaborates with global leadership to integrate regional insights into the worldwide strategy for oncology and respiratory medicines. Through the implementation of robust financial controls and performance metrics, the Chief Financial Officer & Chief Financial Officer, Andean Cluster drives operational excellence and supports the expansion of the company footprint across the South American market.

Richard Hasselbusch, the Vice President and Chief Financial Officer, Global Operations and Information Technology at AstraZeneca, directs the financial strategy for the manufacturing, supply chain, and digital infrastructure divisions. Hasselbusch manages the capital expenditure for global production facilities, ensuring that the company maintains the capacity to deliver high-quality prescription medicines worldwide. By overseeing the financial performance of the IT department, the Vice President and Chief Financial Officer, Global Operations and Information Technology drives the digital transformation necessary for modern drug discovery. This role involves optimizing the cost structure of global operations to improve margins while maintaining rigorous quality standards. Richard Hasselbusch collaborates with the technology team to implement scalable systems that support the research and development efforts of the organization. Through the integration of financial and operational data, the Vice President and Chief Financial Officer, Global Operations and Information Technology ensures that the company maintains a resilient and efficient global supply chain.

Gary Teo, the Chief Financial Officer, Cluster (Vietnam, Philippines) at AstraZeneca, directs the financial operations for the Southeast Asian cluster, focusing on revenue growth and market penetration. Teo manages the local financial planning, risk assessment, and resource allocation to support the commercialization of the pharmaceutical portfolio in these key emerging markets. By overseeing the financial health of the cluster, the Chief Financial Officer, Cluster (Vietnam, Philippines) ensures that the company maintains a strong competitive position in the region. This role involves navigating local regulatory requirements and economic conditions to optimize the profitability of the oncology and respiratory medicine lines. Gary Teo collaborates with regional leadership to align local strategies with the global objectives of the organization. Through the implementation of rigorous financial oversight and performance management, the Chief Financial Officer, Cluster (Vietnam, Philippines) drives the expansion of the company footprint, ensuring that patients in the region have access to life-saving treatments.

Renee Iacona, the Chief Operating Officer, Oncology Research & Development at AstraZeneca, manages the operational execution of the oncology pipeline, from early-stage discovery to clinical trials. Iacona oversees the laboratory resources, project timelines, and cross-functional research teams required to advance cancer therapies. By optimizing the research and development processes, the Chief Operating Officer, Oncology Research & Development ensures that the company maintains a steady flow of innovative medicines. This role involves coordinating with the scientific leadership to prioritize high-potential projects and allocate resources effectively. Renee Iacona monitors the performance of clinical development programs, ensuring that the organization meets its milestones in the competitive oncology market. Through the implementation of efficient operational frameworks, the Chief Operating Officer, Oncology Research & Development supports the mission of the company to transform cancer care, driving the development of targeted treatments that significantly improve patient survival rates and quality of life.

David Auerbach, the Strategy, Transformation Operations Leader & Global Chief Operating Officer, Head of Tmo, Oncology Research & Development at AstraZeneca, architects the long-term strategic transformation of the oncology research division. Auerbach manages the operational integration of new technologies and processes to accelerate the drug discovery lifecycle. By leading the transformation management office, the Strategy, Transformation Operations Leader & Global Chief Operating Officer, Head of Tmo, Oncology Research & Development ensures that the research organization remains agile and focused on high-impact innovation. This role involves coordinating with global leadership to align the research strategy with the commercial goals of the company. David Auerbach monitors the performance of the research pipeline, identifying opportunities for process improvement and resource optimization. Through the implementation of strategic initiatives, the Strategy, Transformation Operations Leader & Global Chief Operating Officer, Head of Tmo, Oncology Research & Development drives the evolution of the oncology portfolio, ensuring that the company continues to lead in the development of breakthrough cancer therapies.

Beth Clement, the Global HR Business Partner & To HR Chief of Staff at AstraZeneca, architects the human capital strategy to support the global research and commercial workforce. Clement aligns talent acquisition and development programs with the scientific mission of the company, ensuring that the organization attracts top-tier talent in oncology and immunology. By overseeing the HR operations and staff coordination, the Global HR Business Partner & To HR Chief of Staff fosters a culture of innovation and high performance. This role involves partnering with C-suite leaders to design organizational structures that facilitate the rapid development of prescription medicines. Beth Clement manages the implementation of global workforce initiatives, ensuring that the company maintains a competitive edge in the biopharmaceutical industry. Through the strategic management of human resources, the Global HR Business Partner & To HR Chief of Staff drives employee engagement and operational efficiency, directly contributing to the success of the global research and development pipeline.

Daniel Evangelista, the Market Access & Strategic Affairs Chief of Staff at AstraZeneca, coordinates the efforts to secure patient access to innovative medicines across global markets. Evangelista manages the strategic alignment between market access teams and the broader commercial organization to ensure that new therapies reach the patients who need them most. By overseeing the operational flow of strategic affairs, the Market Access & Strategic Affairs Chief of Staff facilitates the navigation of complex reimbursement landscapes and regulatory frameworks. This role involves working with senior leadership to define the market entry strategy for oncology and rare disease portfolios. Daniel Evangelista monitors the impact of policy changes on the commercial presence of the company, providing the insights necessary for informed decision-making. Through the coordination of cross-functional teams, the Market Access & Strategic Affairs Chief of Staff drives the successful commercialization of the pipeline, ensuring that the scientific advancements of the company translate into improved patient outcomes.